The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolter, P, Stefan, C, Decallonne, B, Dumez, H, Bex, M, Carmeliet, P, Schöffski, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527784/
https://www.ncbi.nlm.nih.gov/pubmed/18665181
http://dx.doi.org/10.1038/sj.bjc.6604497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527784/
https://www.ncbi.nlm.nih.gov/pubmed/18665181
http://dx.doi.org/10.1038/sj.bjc.6604497

Ejemplares similares